Alirocumab - an overview | ScienceDirect Topics
Praluent Full Prescribing Information, Dosage & Side Effects | MIMS Hong Kong
Outcome trials of PCSK9 inhibitors (evolucumab, alirocumab, bococizumab). | Download Table
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study | Journal of the American Heart Association
Alirocumab (Praluent) - Werking & Bijwerkingen - Simpto.nl
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events | NEJM
Merck & Co. Has Come Up With Very Powerful Pill Against 'Bad' Cholesterol | BioPharma Media
PCSK9 inhibitors
Belgian data of ODYSSEY APPRISE: stringent LDL‐c targets are in reach when using all available tools - Verdickt - - International Journal of Clinical Practice - Wiley Online Library
Alirocumab - wikidoc
Outcome trials of PCSK9 inhibitors (evolucumab, alirocumab, bococizumab). | Download Table
Instituut Verantwoord Medicijngebruik
ALIROCUMAB : MECHANISM OF ACTION, PHARMACOKINETICS, SAFETY, AND CLINICAL OUTCOMES | Pharmaceutical Journal of Indonesia
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocu | VHRM
JCM | Free Full-Text | Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy | HTML
PCSK9 inhibitors mechanism of action. (A) PCSK9 is primarily secreted... | Download Scientific Diagram
BIJLAGE I SAMENVATTING VAN DE PRODUCTKENMERKEN - PDF Gratis download
BIJLAGE I SAMENVATTING VAN DE PRODUCTKENMERKEN - PDF Gratis download
Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study | Lipids in Health and Disease | Full Text
Frontiers | Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders | Neuroscience
New Pharmacological Approaches to Target PCSK9 | SpringerLink
